

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/025609 A1

(51) International Patent Classification:

A61K 9/14 (2006.01) A61K 47/14 (2017.01)
A61K 31/7072 (2006.01) A61K 47/38 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/000027

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

26 July 2023 (26.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/392,304 26 July 2022 (26.07.2022) US

(71) Applicant: **WELLSTAT THERAPEUTICS CORPORATION** [US/US]; 14200 Shady Grove Road, Suite 600, Rockville, MD 20850 (US).

(72) Inventors: **BAMAT, Michael, Kevin**; 8609 Redcoat Lane, Potomac, MD 20854 (US). **GAO, Yi**; 210 Baltusrol Drive, Vernon Hills, IL 60061 (US). **MILLER, Jeffrey, A.**; 316 Clearfield Drive, Lincoln University, PA 19352 (US). **QIU, Yihong**; 210 Baltusrol Drive, Vernon Hills, IL 60061 (US). **VON BORSTEL, Reid, W.**; 10500 Great Arbor Drive, Potomac, MD 20854 (US).

(74) Agent: **KREISLER, Lewis, J.**; Wellstat Management Company, LLC, 14200 Shady Grove Road, Suite 600, Rockville, MD 20850 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: URIDINE TRIACETATE AMORPHOUS FORMULATION AND USES THEREOF

(57) Abstract: There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability. They can be used to deliver exogenous uridine to a mammalian subject in need thereof, for example a subject who has an energy failure disorder or certain other conditions.

WO 2024/025609 A1